Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Uno studio sul MACI in pazienti di età compresa tra 10 e 17 anni con difetti condrali o osteocondrali sintomatici del ginocchio (PEAK)

30 ottobre 2026 aggiornato da: Vericel Corporation

Uno studio clinico prospettico, in aperto, randomizzato, concomitante con controllo attivo, longitudinale, multicentrico, di fase 3 sulla sicurezza e l'efficacia di MACI in pazienti di età compresa tra 10 e 17 anni con difetti condrali o osteocondrali sintomatici del ginocchio dovuti a osteocondrite dissecante o Trauma acuto

The objective of this study is to compare the efficacy and safety of MACI® vs arthroscopic microfracture in the treatment of participants aged 10 to 17 years with symptomatic articular chondral or osteochondral defects of the knee.

Panoramica dello studio

Descrizione dettagliata

This is a 2-year prospective, multicenter, randomized, open-label, parallel group clinical trial; a total of 45 participants, ages 10 to 17 years, will be randomized to receive a 1-time treatment with MACI or microfracture (2:1, 30 MACI:15 microfracture).

After meeting screening criteria at the initial visit, all participants will have a screening arthroscopy to further assess study eligibility. During the screening arthroscopy, participants will be further evaluated against entry criteria. Cartilage lesion size will be measured prior to any cartilage repair procedure and randomization. All participants who meet the eligibility criteria and are considered suitable for treatment in the study will have a cartilage biopsy taken prior to randomization to study treatment. Eligible participants will be randomized during the screening arthroscopy procedure to receive either MACI or microfracture treatment. Participants randomized to microfracture will undergo the procedure during the screening arthroscopy.

All biopsied tissue will be sent to the Vericel manufacturing facility in Massachusetts, where the sample will be processed to isolate the autologous chondrocytes. Cells from participants randomized to the MACI group will be used in the preparation of the MACI implant; cells from participants randomized to the microfracture group will be cryopreserved.

Participants randomized to treatment with MACI will return within 12 weeks of the screening arthroscopy to undergo the chondrocyte implantation procedure via arthrotomy. Participants are to follow a recommended postoperative rehabilitation program and compliance with the rehabilitation schedule will be monitored.

Participants will be followed post-study treatment for 2 years (104 Weeks).

Tipo di studio

Interventistico

Iscrizione (Stimato)

45

Fase

  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • California
      • Palo Alto, California, Stati Uniti, 94304
        • Reclutamento
        • Stanford University School of Medicine
        • Contatto:
        • Investigatore principale:
          • Kevin Shea
      • Sacramento, California, Stati Uniti, 95817
        • Reclutamento
        • Shriners Hospital for Children Northern California
        • Investigatore principale:
          • Brian Haus
        • Contatto:
      • Sacramento, California, Stati Uniti, 95817
        • Reclutamento
        • University of California Davis Lawrence J. Ellison Ambulatory Care Center Orthopaedic Surgery
        • Investigatore principale:
          • Brian Haus
        • Contatto:
    • Louisiana
      • New Orleans, Louisiana, Stati Uniti, 70121
        • Reclutamento
        • Ochsner Health System-Elmwood
        • Contatto:
        • Investigatore principale:
          • Brian Godshaw
    • Maryland
      • Baltimore, Maryland, Stati Uniti, 21224
        • Reclutamento
        • Johns Hopkins Hospital
        • Contatto:
          • Rushyuan Jay Lee, MD
          • Numero di telefono: 443-997-2663
          • Email: rlee74@jhmi.edu
        • Contatto:
        • Investigatore principale:
          • Rushyuan Jay Lee
    • Michigan
      • Ann Arbor, Michigan, Stati Uniti, 48106
        • Reclutamento
        • University of Michigan Medsport Orthopaedic Surgery
        • Contatto:
        • Investigatore principale:
          • Eileen Crawford
    • New York
      • The Bronx, New York, Stati Uniti, 10467
        • Completato
        • Montefiore Medical Center/Albert Einstein College of Medicine
    • Ohio
      • Akron, Ohio, Stati Uniti, 44308
        • Reclutamento
        • Akron Children's Hospital
        • Contatto:
        • Investigatore principale:
          • John Polousky
      • Columbus, Ohio, Stati Uniti, 43202
        • Reclutamento
        • The Ohio State University Jameson Crane Sports Medicine Institute
        • Contatto:
        • Investigatore principale:
          • Christopher Kaeding
    • Pennsylvania
      • Philadelphia, Pennsylvania, Stati Uniti, 19104
        • Reclutamento
        • Penn Medicine University City
        • Contatto:
        • Investigatore principale:
          • James Carey
      • Philadelphia, Pennsylvania, Stati Uniti, 19104
        • Reclutamento
        • The Children's Hospital of Philadelphia - The Hub for Clinical Collaboration
        • Contatto:
        • Investigatore principale:
          • Theodore Ganley
    • Rhode Island
      • East Providence, Rhode Island, Stati Uniti, 02914
        • Reclutamento
        • University Orthopedics, Inc.
        • Contatto:
        • Investigatore principale:
          • Nicholas Lemme
    • Texas
      • Houston, Texas, Stati Uniti, 77094
        • Completato
        • Texas' Children Hospital
      • Plano, Texas, Stati Uniti, 75024
        • Completato
        • Children's Medical Center Plano
    • Wisconsin
      • Milwaukee, Wisconsin, Stati Uniti, 53201
        • Reclutamento
        • Children's Hospital of Wisconsin
        • Contatto:
        • Investigatore principale:
          • John Erickson

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 10 anni a 17 anni (Bambino)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Age 10 to 17 years at the time of planned randomization

  • Symptomatic cartilage or osteochondral defects

  • One or more International Cartilage Repair Society (ICRS) Grade III or IV chondral or unsalvageable osteochondral defects located on the femoral condyles and/or trochlea amenable to treatment with the surgical procedure determined at randomization (MACI or microfracture).

    1. Concurrent ICRS Grade I and II defects are acceptable on the tibia if they remain untreated (or are treated with debridement only) at the time of study treatment.
    2. Participants with a potentially re-attachable osteochondral fragment, identified by magnetic resonance imaging (MRI) and that has not previously been repaired, may be consented to the study and undergo baseline assessments per protocol and prior to confirmatory arthroscopy (Visit 2). At arthroscopy, an attempt will be made to reattach the osteochondral fragment. If this is successful, the participant will be excluded from the study and deemed an intra-operative screen failure. If the attempted reattachment fails and no other exclusion criteria apply, the participant may continue in the PEAK study: a MACI biopsy will be taken, the participant will be randomized and treated per protocol.
  • At least 1 defect size ≥1.5 cm2 on the patella, femoral condyles and/or the trochlea; defects include OCD lesions with a bone lesion depth of ≤6 mm and does not require a bone graft.

  • Salvageable OCD lesions must have failed prior conservative and a reparative treatment, and the participant still experiences pain associated with the osteochondral lesion. Participants with defects as a result of trauma or unknown etiology are eligible regardless of prior treatments.

  • Stable target knee (i.e., anterior and posterior cruciate ligaments should be free of laxity as well as stable and intact). Ligament repair or reconstruction procedures are allowed prior to screening arthroscopy.

  • Intact meniscus or partial meniscus (at least 50% of functional meniscus remaining) in the target knee. Meniscal repair or resection might be performed either staged or concurrent with the cartilage repair procedure provided that the surgeon was able to confirm that at least 50% of functional meniscus would remain after the corrective meniscal treatment.

  • Written informed consent

Exclusion Criteria:

  • Any surgery on the target knee joint within 6 months prior to Screening (not including diagnostic arthroscopy)

  • Previous investigational drug or device use within 3 months prior to Screening

  • Avascular necrosis of the target knee (other than potential OCD lesion to be treated)

  • Participants with uninvolved open growth plates where the surgery necessitates crossing the growth plate, or where the depth of the lesion crosses the growth plate

  • ICRS Grade III or IV chondral or unsalvageable osteochondral defects located on the tibia or any lesion that is bipolar to the index lesion

  • Malalignment requiring concurrent osteotomy to correct tibial-femoral or patella-femoral alignment (prior guided growth treatment is not exclusionary)

  • Symptomatic musculoskeletal conditions in the lower limbs that could impede measurement of efficacy for the target knee joint

  • Concomitant inflammatory disease or other conditions that affects the joints (eg, rheumatoid arthritis, metabolic bone disease, psoriasis, symptomatic chondrocalcinosis)

  • Known history of septic arthritis in the index knee joint

  • Current malignancy or treatment for malignancy within the past 5 years

  • Known history of hypersensitivity to gentamicin, other aminoglycosides, or products of porcine or bovine origin

  • Females who are pregnant or lactating

  • Participants who, in the opinion of the Investigator, have significant medical or psychosocial problems that warrant exclusion. Examples of significant problems included but are not limited to:

    • Any condition that has potential for negatively impacting intra or postoperative course
    • Conditions that limit compliance with rehabilitation program
    • Any condition that has potential for significantly limiting participant's ability to assess postoperative knee function
    • Any condition, psychiatric or otherwise, that would preclude informed consent/assent, consistent follow-up, or compliance with any aspect of the study
    • Participant is currently abusing drugs or alcohol or, in the opinion of the Investigator, at high risk for poor compliance

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: MACI

autologous cultured chondrocytes on porcine collagen membrane

autologous cultured chondrocytes on porcine collagen membrane

Altro: microfracture

surgical procedure

Arthroscopic microfracture treatment

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Proportion of Participants Who Achieve ≥ 10-point Improvement From Baseline in KOOS-Child Pain and Function (Sports and Recreational Activities) Subscale Scores
Lasso di tempo: Baseline and Week 104

A responder is defined as a participant with ≥ 10-point change (improvement) in both the KOOS-Child Pain and Function (Sports and Recreational activities) scores from Baseline scores. The Knee and Osteoarthritis Outcome Score for Children (KOOS-Child) is a validated knee-specific instrument developed to assess the participant's opinion of their knee and associated problems. KOOS consists of 5 subscales: Pain, Function in sports and recreational activities, other Symptoms, Function in activities of daily living (ADL), and knee related Quality of life (QOL).

Baseline and Week 104

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change from Baseline in KOOS-Child subscores
Lasso di tempo: Baseline and Week 104

The Knee and Osteoarthritis Outcome Score for Children (KOOS-Child) is a validated knee-specific instrument developed to assess the participant's opinion of their knee and associated problems. KOOS consists of 5 subscales: Pain, Function in sports and recreational activities, other Symptoms, Function in activities of daily living (ADL), and knee related Quality of life (QOL).

Baseline and Week 104
Change from Baseline in KOOS-Child subscores
Lasso di tempo: Baseline and Week 52

The Knee and Osteoarthritis Outcome Score for Children (KOOS-Child) is a validated knee-specific instrument developed to assess the participant's opinion of their knee and associated problems. KOOS consists of 5 subscales: Pain, Function in sports and recreational activities, other Symptoms, Function in activities of daily living (ADL), and knee related Quality of life (QOL).

Baseline and Week 52

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Treatment Emergent Adverse Events
Lasso di tempo: Week 104

A treatment emergent untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related.

Week 104

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Direttore dello studio: Jonathan Hopper, BSc (Hons), MB ChB, FRCSEd, Vericel Corporation

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

24 ottobre 2018

Completamento primario (Stimato)

1 febbraio 2030

Completamento dello studio (Stimato)

1 febbraio 2030

Date di iscrizione allo studio

Primo inviato

4 aprile 2018

Primo inviato che soddisfa i criteri di controllo qualità

15 luglio 2018

Primo Inserito (Effettivo)

17 luglio 2018

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

3 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

30 ottobre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi